Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Gilead Sciences to Acquire Immunomedics for $21 Billion in Cash

TheMotleyFool

0 0

Gilead Sciences to Acquire Immunomedics for $21 Billion in Cash

Gilead Sciences' (NASDAQ: GILD) mission to create a better oncology portfolio took a big step forward on Sunday. The company best known for antiviral treatments made Immunomedics (NASDAQ: IMMU) a juicy buyout offer that values the recently successful cancer drug developer at $21 billion.

Immunomedics shareholders will receive $88 per share in cash from Gilead Sciences when the deal closes, most likely before the end of the year. The price Gilead offered is 108% more than Immunomedics' most recent closing price.

Image source: Getty Images.

Source Fool.com

Like: 0

GILD

Share